Recall -- Firm Press Release
FDA posts press releases and other notices of recalls and market withdrawals from the firms involved as a service to consumers, the media, and other interested parties. FDA does not endorse either the product or the company.
Samantha Lynn Inc. Is Voluntarily Recalling all lots of Reumofan Plus Tablets Due to Undeclared Drug Ingredients
FOR IMMEDIATE RELEASE - August 31, 2012 - Samantha Lynn Inc. is voluntarily recalling Reumofan Plus Tablets to the consumer level due to findings of undeclared drug ingredients. Customers may have received products through the U.S. Postal service with the return addressee referenced as Samantha Lynn, Inc., or through any association with the email address firstname.lastname@example.org, and the websites Naturallifeandhealth.com and Reumofanshop.com.
The Food and Drug Administration (FDA) sample analysis has found the product to contain methocarbamol, dexamethasone, and diclofenac. Use of this product could result in serious and life threatening injuries. Samantha Lynn Inc. has not received any reports of adverse events related to this recall.
The product is used as a treatment for muscle pain, arthritis, osteoporosis, bone cancer and other conditions. The affected Reumofan Plus lots are all lots having expiration dates through 2016. The product is marketed in a green bottle containing 30 lavender round tablets and is distributed nationwide via the internet.
If you purchased Reumofan Plus from Samantha Lynn, Inc, or through the email address email@example.com, or the websites Naturallifeandhealth.com and Reumofanshop.com, you will receive an email shortly notifying you of your options. If you purchased Reumofan Plus from elsewhere, DO NOT CONTACT Samantha Lynn Inc. Contact your local FDA office. Consumers that have Reumofan Plus should be aware that the product may pose a serious health risk. Consumers who are taking these products or who have recently stopped taking Reumofan plus should immediately consult a health care professional.
Consumers with questions regarding this recall can contact Samantha Lynn Inc. by email to firstname.lastname@example.org Monday – Friday between 8am to 5pm, Pacific Standard Time. Consumers should contact their physician or healthcare provider if they have any health questions or have experienced any problems that may be related to taking or using this product.
Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax.
- Online: www.fda.gov/medwatch/report.htm1
- Regular Mail: use postage-paid, pre-addressed Form FDA 3500 available at:
Mail to address on the pre-addressed form.
- Fax: 1-800-FDA-0178
This recall is being conducted with the knowledge of the US Food and Drug Administration